A case involving Wyeth, the pharmaceutical company, that was argued before the U.S. Supreme Court yesterday is the latest in an intensifying national debate over "preemption," a doctrine under which
companies can be shielded under federal law from state lawsuits. Business groups strongly favor preemption, while state regulators fear it hurts consumers.
Read the whole story at Washington Post »
